Quantification of N-acetyl-seryl-aspartyl-lysyl-proline in hemodialysis patients administered angiotensin-converting enzyme inhibitors by stable isotope dilution liquid chromatography–tandem mass spectrometry

Inoue, Kōichi; Ikemura, Ayaka; Tsuruta, Yoshinari; Watanabe, Kenji; Tsutsumiuchi, Kaname; Hino, Tomoaki; Oka, Hisao

doi:10.1016/j.jpba.2010.10.009

Cited by 12 publications

(22 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Increases in plasma AcSDKP level have been reported in patients with various diseases, such as chronic renal failure, 18,19) chronic heart failure 24) and hematologic malignancy.…”

Section: Discussionmentioning

confidence: 99%

“…18) We reported previously that plasma AcSDKP-IS levels in patients with ESRD before kidney transplantation were higher than those of healthy subjects (1.29± 0.56 vs. 0.29± 0.07 pmol/ mL), 21) which was consistent with past reports of elevated plasma AcSDKP levels in patients with chronic renal failure. 18,19) Plasma AcSDKP-IS level decreased significantly from day 3 after kidney transplantation compared to before kidney transplantation. The degrees of decrease in plasma AcSDKP-IS level were not different between living and cadaveric kidney transplant recipients (data not shown).…”

Section: )mentioning

confidence: 94%

“…16,17) To the best of our knowledge, only two studies have examined plasma AcSDKP levels in patients with end stage renal disease (ESRD). 18,19) Le Meur et al 18) found that plasma AcSDKP level is elevated in hemodialysis patients and that residual renal function independently predicts plasma AcSDKP level. Inoue et al 19) also reported elevated plasma AcSDKP level in hemodialysis patients.…”

Section: Significant Decrease In Plasma N-acetyl-seryl-aspartyl-lysylmentioning

confidence: 99%

“…18,19) Le Meur et al 18) found that plasma AcSDKP level is elevated in hemodialysis patients and that residual renal function independently predicts plasma AcSDKP level. Inoue et al 19) also reported elevated plasma AcSDKP level in hemodialysis patients. These reports suggest that impairment of renal function may have a significant impact on plasma AcSDKP level.…”

Section: Significant Decrease In Plasma N-acetyl-seryl-aspartyl-lysylmentioning

confidence: 99%

See 3 more Smart Citations

Significant Decrease in Plasma <i>N</i>-Acetyl-seryl-aspartyl-lysyl-proline Level in Patients with End Stage Renal Disease after Kidney Transplantation

Suzuki

Katagiri

Sato

et al. 2014

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

N-Acetyl-seryl-aspartyl-lysyl-proline (AcSDKP) is an endogenous peptide released from its precursor (thymosin-β4) by prolyl oligopeptidase. AcSDKP is a natural inhibitor of pluripotent hematopoietic stem cell proliferation and is normally found in human plasma. AcSDKP has been shown to be a potent angiogenic factor and to suppress renal fibroblast proliferation. Impairment of renal function has been suggested to have a significant impact on plasma AcSDKP level. The aim of this study was to assess whether improvement of renal function after kidney transplantation has an impact on plasma AcSDKP-like immunoreactive substance (IS) level. Fourteen patients with end stage renal disease (ESRD) who were scheduled to undergo the first kidney allograft transplantation were enrolled. Plasma AcSDKP-IS levels were measured before and 3, 7, 10, 14, 21, 30, 60 and 90 d after kidney transplantation. Plasma AcSDKP-IS level decreased significantly from day 3 after kidney transplantation compared to before kidney transplantation. Creatinine clearance increased significantly from day 7 after kidney transplantation. A significant negative correlation was observed between creatinine clearance and plasma AcSDKP-IS level from before transplantation to 90 d after kidney transplantation. Stepwise multiple regression analysis identified creatinine clearance as the only significant independent factor associated with plasma AcSDKP-IS levels. These results suggest that recovery of kidney function after kidney transplantation may lead to a decrease in plasma AcSDKP level in patients with ESRD, and that plasma AcSDKP level may depend largely on renal function.

show abstract

“…Increases in plasma AcSDKP level have been reported in patients with various diseases, such as chronic renal failure, 18,19) chronic heart failure 24) and hematologic malignancy.…”

Section: Discussionmentioning

confidence: 99%

Section: )mentioning

confidence: 94%

Section: Significant Decrease In Plasma N-acetyl-seryl-aspartyl-lysylmentioning

confidence: 99%

Section: Significant Decrease In Plasma N-acetyl-seryl-aspartyl-lysylmentioning

confidence: 99%

See 2 more Smart Citations

Significant Decrease in Plasma <i>N</i>-Acetyl-seryl-aspartyl-lysyl-proline Level in Patients with End Stage Renal Disease after Kidney Transplantation

Suzuki

Katagiri

Sato

et al. 2014

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

show abstract

“…The pooled human plasma was obtained from Nissui Pharmaceutical Co. (Tokyo, Japan). The Ac-SDKP-13 C 6 , 15 N 2 was synthesized based on previous report (Inoue et al, 2011 We recruited subjects from November to December 2010 at Meiyo Clinic, Toyohashi City in Aichi, Japan. This study was conducted with all subjects' written, informed consent and approved by the institutional ethical board for epidemiological studies.…”

Section: Experimental Chemicals and Reagentsmentioning

confidence: 99%

On‐line solid‐phase extraction LC‐MS/MS for the determination of Ac‐SDKP peptide in human plasma from hemodialysis patients

Inoue

Ikemura

Tsuruta

et al. 2011

Biomedical Chromatography

Self Cite

View full text Add to dashboard Cite

We developed a high-throughput method based on on-line solid-phase extraction liquid chromatography tandem mass spectrometry (SPE-LC-MS/MS) to determine N-terminal thymosin-β fragment peptide (N-acetyl-seryl-aspartyl-lysyl-proline, Ac-SDKP) in human plasma samples. Quantification of Ac-SDKP was performed using direct injection for on-line SPE based on C(18), reversed-phase LC separation and stable isotope dilution electrospray ionization-MS/MS in multiple reaction-monitoring (MRM) mode. The Ac-SDKP-(13)C(6), (15)N(2) (m/z 496 → 137) was synthesized for the internal standard. The MRM ion for Ac-SDKP was m/z 488 → 129 (quantitative ion)/226. The limit of detection and lower limit of quantitation were 0.05 and 0.1 ng/mL in standard solution, respectively. Recovery values were 98.3-100.4% with inter-day (relative standard deviation, RSD, 0.4-14.1%) and intra-day (RSD, 0.8-19.7%) assays. This method was applied to the measurement of Ac-SDKP levels in plasma from hemodialyzed subjects. Concentrations were 0.59 ± 0.23 ng/mL (pre-hemodialyzed subjects, n = 9) and 0.44 ± 0.19 ng/mL (post-hemodialyzed subjects, n = 9). All plasma Ac-SDKP levels were decreased by dialysis. Thus, plasma Ac-SDKP was decreased through dialysis in chronic kidney disease. The findings in this study will be useful for the treatment of anemia in chronic kidney disease with dialysis.

show abstract

Rapid Detection of Irreversible Acetylcholineasterase Inhibitor by Mass Spectrometry Assay

et al. 2012

View full text Add to dashboard Cite

Here we developed a rapid method to detect acetylcholinesterase (AChE) activity by matrix‐assisted laser desorption/ionization Fourier transform mass spectrometry (MALDI‐FTMS) for screening irreversible AChE inhibitors. Due to its good salt‐tolerance and low sample consumption, MALDI‐FTMS could facilitate rapid detection, especially detection in real application. AChE activity was determined through calculating abundance of substrate and product in mass spectrometry. By this approach, we investigated the relation of organophosphorous (OP) concentrations and AChE inhibition. Shown in different inhibition curves from different OP pesticides, enzyme inhibitions still kept good correlation with concentration of OPs. Finally, this AChE‐inhibited method was applied to screen whole bloods of four decedents and discuss their death reason. In contrast to healthy persons, three of decedents showed low AChE activity, and probably died for irreversible AChE inhibitors. Through the following detecting in GC‐MS/MS, the possible death reason of these three decedents was confirmed, and another decedent actually died for sumicidin, a non‐AChE inhibitor. It demonstrated that screening irreversible AChE inhibitors by detecting enzyme activity in MALDI‐FTMS provided fast and accurate analysis results and excluded another toxicants not functioning on AChE. This method offered alternative choices for indicating the existence of enzyme inhibitors.

show abstract

Quantification of N-acetyl-seryl-aspartyl-lysyl-proline in hemodialysis patients administered angiotensin-converting enzyme inhibitors by stable isotope dilution liquid chromatography–tandem mass spectrometry

Cited by 12 publications

References 16 publications

Significant Decrease in Plasma <i>N</i>-Acetyl-seryl-aspartyl-lysyl-proline Level in Patients with End Stage Renal Disease after Kidney Transplantation

Significant Decrease in Plasma <i>N</i>-Acetyl-seryl-aspartyl-lysyl-proline Level in Patients with End Stage Renal Disease after Kidney Transplantation

On‐line solid‐phase extraction LC‐MS/MS for the determination of Ac‐SDKP peptide in human plasma from hemodialysis patients

Rapid Detection of Irreversible Acetylcholineasterase Inhibitor by Mass Spectrometry Assay

Contact Info

Product

Resources

About